{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-002529","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2022-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.094332+00:00","generated_at":"2026-06-26T08:22:37.292925+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aptose appoints Philippe Ledru as CCO; CFO Jotin Marango resigns","bullets":["Philippe Ledru appointed CCO effective April 6, 2022; base salary $410K with up to 40% bonus.","Dr. Jotin Marango resigns as CFO/CBO to pursue other opportunity; CEO Dr. Rice assumes CAO role.","Ledru receives a stock option grant for 600,000 common shares under Aptose's 2021 Stock Incentive Plan.","Ledru previously held senior commercial roles at Merck and Novartis, including oncology pipeline leadership."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-002529","json":"https://secwatch.observer/filing/0001171843-22-002529.json","markdown":"https://secwatch.observer/filing/0001171843-22-002529.md","text":"https://secwatch.observer/filing/0001171843-22-002529.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184322002529/0001171843-22-002529-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184322002529/f8k_041122.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T08:22:37.292925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f47a8d8b0","claim":"Philippe Ledru was appointed as Chief Commercial Officer at Aptose Biosciences Inc..","evidence_excerpt":"On April 6, 2022, Aptose Biosciences Inc. appointed Mr. Philippe Ledru as its Chief Commercial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000117184322002529/0001171843-22-002529-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"},{"claim_id":"27963f80e2","claim":"Jotin Marango departed as Senior Vice President, Chief Financial Officer and Chief Business Officer at Aptose Biosciences Inc..","evidence_excerpt":"Aptose also announced on April 07, 2022 that Dr. Jotin Marango, Senior Vice President, Chief Financial Officer and Chief Business Officer, is resigning to pursue another opportunity.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000117184322002529/0001171843-22-002529-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigning"},{"label":"Role","value":"Senior Vice President, Chief Financial Officer and Chief Business Officer"}],"fact_type":"executive_change"},{"claim_id":"779c14f697","claim":"Dr. Rice changed role as Chief Accounting Officer at Aptose Biosciences Inc..","evidence_excerpt":"Dr. Rice will serve as Chief Accounting Officer, and with Ms. Janet Clennett, Vice President of Finance, will assume financial responsibilities until a permanent CFO is announced.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000117184322002529/0001171843-22-002529-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"will serve as"},{"label":"Role","value":"Chief Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}